HIV污名限制几内亚PMTCT效果:ANRS 12344-DIAVINA研究
该前瞻性研究在几内亚科纳克里Ignace Deen医院评估结合早期婴儿诊断与强化抗逆转录病毒预防的高危婴儿策略可行性。6493名分娩妇女中6141人(94.6%)接受HIV检测,114人(1.9%)HIV阳性,纳入51名高危母亲及其56名婴儿。强化预防在48/56名婴儿(86%,95%CI 77%-95%)中启动,但未披露HIV状态与自我污名相关(85% vs 44%,P=0.02),真实高危婴儿更易失访(44% vs 8%,P<0.01)。
要点
- 强化抗逆转录病毒预防和出生时早期婴儿诊断广泛可行。
- 母亲自我披露HIV状态和抗逆转录病毒用药不能充分评估母婴传播风险。
- 反对污名化行动对改善PMTCT至关重要。
核心结论
- 强化抗逆转录病毒预防和出生时早期婴儿诊断广泛可行。
- 母亲对HIV状态和抗逆转录病毒用药的自我披露不能充分评估母婴传播风险,主张临近分娩时测量母亲血浆病毒载量。
- 反对污名化的行动对改善PMTCT至关重要。
研究设计与样本
- 前瞻性ANRS 12344-DIAVINA研究,在几内亚科纳克里Ignace Deen医院通过访谈母亲识别高危婴儿,评估结合早期婴儿诊断和强化抗逆转录病毒预防策略的可行性。
- 6493名妇女入院分娩,6141名(94.6%)接受HIV检测,114名(1.9%)HIV阳性;纳入51名高危妇女及其56名婴儿。
主要发现
- 出生时采集婴儿血样用于早期婴儿诊断,48/56名婴儿(86%,95%CI 77%-95%)启动强化抗逆转录病毒预防。
- 35%的婴儿因非严重贫血接受铁剂补充。
- 回顾性测量分娩时母亲血浆病毒载量显示52%的妇女pVL<400 copies/mL,归因于未披露的HIV状态和/或抗逆转录病毒用药。
- 未披露HIV状态与自我污名相关(85% vs 44%,P=0.02)。
- 基于分娩时母亲pVL结果,真实高危婴儿较低危婴儿更频繁失访(44% vs 8%,P<0.01),且与母亲污名相关(69% vs 31%,P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nearly half of HIV-infected children worldwide are born in West and Central African countries where access to prevention of mother-to-child transmission of HIV (PMTCT) programmes is still limited. WHO recommends reinforced antiretroviral prophylaxis for infants at high risk of mother-to-child transmission of HIV (MTCT) but its implementation needs further investigation in the field. METHODS: The prospective ANRS 12344-DIAVINA study evaluated the feasibility of a strategy combining early infant diagnosis (EID) and reinforced antiretroviral prophylaxis in high-risk infants as identified by interviews with mothers at Ignace Deen Hospital, Conakry, Guinea. RESULTS: 6493 women were admitted for delivery, 6141 (94.6%) accepted HIV testing and 114 (1.9%) were HIV positive. Among these, 51 high-risk women and their 56 infants were included. At birth, a blood sample was collected for infant EID and reinforced antiretroviral prophylaxis was initiated in 48/56 infants (86%, 95% CI 77%-95%). Iron supplementation was given to 35% of infants for non-severe anaemia. Retrospective measurement of maternal plasma viral load (pVL) at delivery revealed that 52% of women had pVL < 400 copies/mL attributable to undisclosed HIV status and/or antiretroviral intake. Undisclosed HIV status was associated with self-stigmatization (85% versus 44%, P = 0.02). Based on the results of maternal pVL at delivery, 'real' high-risk infants were more frequently lost to follow-up (44% versus 8%, P < 0.01) in comparison with low-risk infants, and this was associated with mothers' stigmatization (69% versus 31%, P < 0.01). CONCLUSIONS: Reinforced antiretroviral prophylaxis and EID at birth are widely feasible. However, mothers' self-disclosure of HIV status and antiretroviral intake do not allow adequate evaluation of MTCT risk, which argues for maternal pVL measurement near delivery. Furthermore, actions against stigmatization are crucial to improve PMTCT.
引用
- Breton G, Diallo OH, Cissé M, et al. HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study. J Antimicrob Chemother. 2022. PMID: 36031792. doi:10.1093/jac/dkac287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。